Ligand Pharmaceuticals, Inc. (LGND)
189.07
-1.13
(-0.59%)
USD |
NASDAQ |
Dec 31, 16:00
188.93
-0.14
(-0.07%)
Pre-Market: 20:00
Ligand Pharmaceuticals Cash from Investing (Quarterly): -353.44M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Merck & Co., Inc. | -283.00M |
| Johnson & Johnson | -542.00M |
| Inspire Medical Systems, Inc. | -11.64M |
| Elanco Animal Health, Inc. | -101.00M |
| Alnylam Pharmaceuticals, Inc. | 501.11M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 13.16M |
| Cash from Financing (Quarterly) | 409.57M |
| Free Cash Flow | 20.43M |
| Free Cash Flow Per Share (Quarterly) | 0.2306 |
| Free Cash Flow to Equity (Quarterly) | -440.50M |
| Free Cash Flow to Firm (Quarterly) | 5.513M |
| Free Cash Flow Yield | 0.55% |